Environment
No direct effect
Neutral — no direct effect identified.
Benefits
- No material direct effect identified.
Risks
- No material direct effect identified.
StateIowaEnacted
SF 2480: A bill for an act relating to the taxation and regulation of alternative nicotine products and vapor products, making appropriations, and including effective date provisions.
COMMITTEE ON APPROPRIATIONS
SF 2480 status: Enacted — Signed by Governor (updated May 26, 2026).
Source
LegiScan
Confidence
High
Analysis basis
LegiScan full bill text
01
What this bill does
Official summary alongside an AI-generated read on where it stands and why.
Overall Score
60OUT OF 100
Score:60/100 civic fit
Risk:Low Risk
Impact:Moderate Impact 60/100
Constitutionality95%
Bipartisan70%
Public opinion65%
Bill summary
What changes
The legislation introduces a new state-level excise tax on alternative nicotine and vapor products ($0.05 per container/unit or ml) and mandates new registration, record-keeping, and electronic reporting requirements for distributors. It also earmarks $3 million annually from the Health Care Trust Fund for pediatric cancer research and therapy at the University of Iowa Stead Family Children’s Hospital.
Who is affected
Distributors, wholesalers, and subjobbers of nicotine and vapor products, as well as pediatric health research programs at the University of Iowa.
Requirements and enforcement
Distributors must obtain licenses, maintain detailed itemized invoices for three years, and file monthly electronic tax returns. Retailers are restricted from claiming lack of physical presence for tax collection purposes.
Costs and funding
Businesses face a $0.05/unit or ml tax, plus potential inventory taxes when tax rates increase, alongside compliance and record-keeping overhead costs.
When it takes effect
The effective date for the regulatory and tax provisions is January 1, 2027.
Potential benefits
Provides reliable funding for pediatric clinical research and creates a more standardized tax environment for nicotine and vapor products.
Risks and tradeoffs
Small business compliance costs may be high; there is a structural reliance on nicotine/vapor sales to fund essential pediatric healthcare.
What is still unknown
The long-term impact on the market demand for vapor products due to the added tax is not quantified, nor is the specific efficacy of future research programs supported by these funds.
02
Impact analysis
✦ AI analysisModeled effects across six domains, estimated from bill text and comparable legislation.
Economy
Critical outlook
40%
Benefits
- Establishes a standardized tax framework for nicotine distributors
- Increases revenue for state health-related trust funds
- Supports state research university funding via earmarked appropriations
Risks
- Adds direct tax burden on vapor and alternative nicotine products
- Imposes administrative costs for compliance and licensing
- Mandates inventory tax payments on stock held during rate hikes
Society
Positive outlook
70%
Benefits
- Secures permanent annual funding for pediatric cancer research
- Increases availability of clinical therapies for children
- Enhances physician-scientist leadership at state health institutions
Risks
- Creates a dependency between public health and nicotine sales
- Concentrates research benefits in a single regional facility
- No direct impact on reducing youth usage or addiction
Technology Industry
No direct effect
Neutral — no direct effect identified.
Benefits
- No material direct effect identified.
Risks
- No material direct effect identified.
Civic Accountability
Positive outlook
60%
Benefits
- Requires electronic filing of tax returns for transparency
- Grants state authorities clear inspection and audit power
- Standardizes record-keeping for better industry oversight
Risks
- Broad authority granted for director-led facility inspections
- Enforcement of inventory taxes can lead to disputes
- Severe penalties for failure to submit required reports
Public Health & Safety
Positive outlook
70%
Benefits
- Provides direct appropriation for pediatric clinical research
- Defines nicotine analogs for clearer health-product oversight
- Funds advanced therapy research at the University of Iowa
Risks
- Provides no new safety standards for vapor products themselves
- Relies on future sales of nicotine products for funding
- Regulatory focus is on taxation rather than consumer safety
03
How trustworthy & consequential it is
Sourcing already shown above, this is what the analysis found worth flagging.
Source
LegiScan
Official bill text or data from LegiScan.
Confidence
High
Information is complete and verified.
Analysis basis
LegiScan full bill text
Source used for this bill's analysis.
Source note
Businesses are subject to inventory tax liabilities based on historical tax definitions
Analysis scope
Economic impact estimates on the retail sector are not explicitly provided
04
Where it stands
Official recordSigned by Governor.
- IntroducedComplete
- CommitteeComplete
- Chamber votesComplete
- Final agreementComplete
- GovernorComplete
- EnactedComplete
05
How it affects your district
✦ Personalized
Set your location
Add your district to see how this bill may affect your community and who to contact.
Your Representatives
Your representatives appear here once you add your location.
06
Take action
Contact your representatives
Let them know how you feel about this bill.
Share your view
Join the discussion and see what others are saying.
Track this bill
Stay updated on progress and changes.